NovaBridge Biosciences
NBP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$138.29M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $138.29 Million |
|---|---|
| Enterprise Value | $-23,637,600.00 |
| Earnings per Share | $-0.16 |
| Beta | 1.6 |
| Outstanding Shares | 115,720,000 |
Return
| Return on Equity | -19.42% |
|---|---|
| Return on Assets | -18.48% |
| Return on Invested Capital | -18.50% |
Valuation & Multiples
| P/E Ratio | -2.09 |
|---|---|
| PEG | 1.72 |
| Price to Sales | - |
| Price to Book Ratio | 1.2 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$33.59 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About I-Mab
30 employees
CEO: Srishti Gupta
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a b...